<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2021.111007</article-id><article-id pub-id-type="publisher-id">MD-40943</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20210100000_58697590.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  PCSK9与肿瘤发生发展关系的研究进展
  Research Progress on the Relationship between PCSK9 and Development of Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>慕</surname><given-names>玉东</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贺</surname><given-names>林</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>陕西省肿瘤医院检验科，陕西 西安</addr-line></aff><aff id="aff3"><addr-line>西安市中心医院心内科，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>42</fpage><lpage>46</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  前蛋白转化酶枯草溶菌素9 (PCSK9)是一种新的前蛋白转换酶，属于枯草蛋白酶亚家族，主要功能是降解低密度脂蛋白受体影响LDL的代谢，已经证实是治疗心血管疾病的有效靶点。随着对PCSK9研究的深入，PCSK9过表达还可引起细胞周期、凋亡、炎症及应激反应等多条通路失调，与肿瘤密切相关。本文旨在探讨PCSK9在肿瘤发生发展中作用的相关性。
   Proprotein convertase subtilisin kexin 9 (PCSK9) is a new protein converting enzyme, belonging to the subfamily of subtilase, whose function is to degrade low density lipoprotein receptor to affect LDL metabolism, which has been proved to be an effective target for the treatment of cardiovascular diseases. With the further study on PCSK9, over-expression of PCSK9 can also cause dysregulation of multiple pathways such as cell cycle, apoptosis, inflammation and stress response, which is closely related to tumors. The purpose of this study was to investigate the correlation of PCSK9 in tumor development.
 
</p></abstract><kwd-group><kwd>PCSK9，肿瘤，血脂, PCSK9</kwd><kwd> Tumor</kwd><kwd> Blood Lipids</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>前蛋白转化酶枯草溶菌素9 (PCSK9)是一种新的前蛋白转换酶，属于枯草蛋白酶亚家族，主要功能是降解低密度脂蛋白受体影响LDL的代谢，已经证实是治疗心血管疾病的有效靶点。随着对PCSK9研究的深入，PCSK9过表达还可引起细胞周期、凋亡、炎症及应激反应等多条通路失调，与肿瘤密切相关。本文旨在探讨PCSK9在肿瘤发生发展中作用的相关性。</p></sec><sec id="s2"><title>关键词</title><p>PCSK9，肿瘤，血脂</p></sec><sec id="s3"><title>Research Progress on the Relationship between PCSK9 and Development of Tumor <sup> </sup></title><p>Yudong Mu<sup>1</sup>, Lin He<sup>1</sup>, Tao Zhang<sup>2</sup></p><p><sup>1</sup>Department of Clinical Laboratory, Tumor Hospital of Shaanxi Province, Xi’an Shaanxi</p><p><sup>2</sup>Department of Cardiology, Xi’an Central Hospital, Xi’an Shaanxi</p><p><img src="//html.hanspub.org/file/7-2170289x4_hanspub.png" /></p><p>Received: Feb. 19<sup>th</sup>, 2021; accepted: Mar. 4<sup>th</sup>, 2021; published: Mar. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/7-2170289x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Proprotein convertase subtilisin kexin 9 (PCSK9) is a new protein converting enzyme, belonging to the subfamily of subtilase, whose function is to degrade low density lipoprotein receptor to affect LDL metabolism, which has been proved to be an effective target for the treatment of cardiovascular diseases. With the further study on PCSK9, over-expression of PCSK9 can also cause dysregulation of multiple pathways such as cell cycle, apoptosis, inflammation and stress response, which is closely related to tumors. The purpose of this study was to investigate the correlation of PCSK9 in tumor development.</p><p>Keywords:PCSK9, Tumor, Blood Lipids</p><disp-formula id="hanspub.40943-formula40"><graphic xlink:href="//html.hanspub.org/file/7-2170289x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-2170289x7_hanspub.png" /> <img src="//html.hanspub.org/file/7-2170289x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin kexin 9, PCSK9)是前蛋白转化酶家族的第9个成员，主要由肝脏分泌，在肝、肾脏、小肠、脑等组织中表达。PCSK9具有四段序列，包括信号肽序列、原结构域序列、催化结构域序列及富含半胱氨酸和组氨酸的c末端区域，产生于细胞内质网，细胞外分泌前为无活性酶原形式 [<xref ref-type="bibr" rid="hanspub.40943-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref2">2</xref>]。PCSK9通过调控低密度脂蛋白受体(LDLR)来调节低密度脂蛋白胆固醇(LDL-C)，具体机制是在肝细胞表面上LDL-C与LDL-R结合，形成囊泡后通过胞吞作用进入细胞内，PCSK9与LDL-R结合后将LDL-R导向溶酶体进行降解，导致肝细胞表面的LDL-R受体减少，从而减少了LDL-C的吸收，升高了血液LDL-C水平 [<xref ref-type="bibr" rid="hanspub.40943-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref4">4</xref>]。</p><p>研究发现胆固醇与癌症的发生密切相关，胆固醇是脂筏结构的关键组分，其通过调节脂筏结构影响信号转导通路，血浆胆固醇水平升高会导致脂筏中胆固醇的积累减少细胞凋亡，促进肿瘤细胞的生长 [<xref ref-type="bibr" rid="hanspub.40943-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref7">7</xref>]。血清中70%的胆固醇以脂蛋白复合物LDL-C的形式存在。胆固醇代谢异常通过影响脂筏结构和功能、促进氧化应激和炎症反应等机制在癌症的发生发展中起一定作用。韩国研究人员 [<xref ref-type="bibr" rid="hanspub.40943-ref8">8</xref>] 的一项前瞻性研究纳入近120万例受试者，进行14年的随访，结果显示，TC与男性前列腺癌、结肠癌和女性乳腺癌发病呈正相关，这个与其他研究也是一致的 [<xref ref-type="bibr" rid="hanspub.40943-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref11">11</xref>]。此外，还有研究发现高TC和LDL-C/HDL-C比值升高的患者结直肠癌远处转移、乳腺癌转移的发生率上升 [<xref ref-type="bibr" rid="hanspub.40943-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref13">13</xref>]。</p><p>凋亡是哺乳动物细胞对生理性、病理性刺激作出的一种快速而机制复杂的反应。细胞凋亡是一个主动的由基因决定的自动结束生命的过程，由于细胞凋亡受到严格的由遗传机制决定的程序性的调控．所以也常常被称为细胞程序性死亡。诱导细胞凋亡的因子可分为物理性因子和化学及生物因子，物理性因子包括射线，较温和的温度刺激等，化学及牛物因子包括活性氧基团和分子等。肿瘤的发生与细胞凋亡紊乱有密切关系，肿瘤细胞的无限生长是肿瘤细胞凋亡受抑制的结果。目前发现两条凋亡的途径 [<xref ref-type="bibr" rid="hanspub.40943-ref14">14</xref>]：一条为内源性途径，也称为线粒体途径；另一条为外源性途径，即死亡受体激活途径。线粒体途径是指当线粒体功能紊乱时凋亡随即启动，它是凋亡发生关键因素。目前发现线粒体调节细胞凋亡有以下3种机制：1) 线粒体电子传递与能量代谢的破坏；2) 细胞氧化状态的改变；3) 线粒体膜通透性改变导致介导细胞凋亡的分子的释放。</p><p>Ranheim [<xref ref-type="bibr" rid="hanspub.40943-ref15">15</xref>] 等人利用微阵列技术探索功能获得性突变D374Y-PCSK9在转染18小时的肝癌HepG2细胞中基因表达通路，发现D374Y-PCSK9在类固醇生物合成、类固醇代谢及胆固醇生物合成的通路中是高表达，而在应激反应、病毒应答及未折叠蛋白质应答通路是低表达。Demidyuk等 [<xref ref-type="bibr" rid="hanspub.40943-ref16">16</xref>] 利用qRT-PCR检测PCs家族在30例病理分型尚不明确的肺癌组织及正常癌旁肺组织的mRNA，发现PCSK9在29例正常组织中均表达，而只在18例肺癌组织中表达，PCSK9在肺癌中呈低表达。Lan等 [<xref ref-type="bibr" rid="hanspub.40943-ref17">17</xref>] 证实PCSK9诱导胆固醇合成基因上调从而导致体内胆固醇减少，此外还发现PCSK9在肝癌Hep G2细胞内除影响胆固醇代谢还可作用其他基因表达通路，而这些通路与胆固醇的代谢是无关，包括蛋白质泛素化、异物质新陈代谢、细胞周期、炎症及应激反应。PCSK9除了在维持胆固醇稳定中的作用外，还与细胞周期、凋亡、炎症及应激反应等多条通路的调控相关，与肿瘤密切相关 [<xref ref-type="bibr" rid="hanspub.40943-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40943-ref19">19</xref>]，具体的作用机制如下。</p></sec><sec id="s6"><title>2. 内源性途径–线粒体途径</title><p>内部凋亡通路又被称为线粒体通路，主要是通过B淋巴细胞瘤-2家族成员作用于线粒体，调控促凋亡因子在细胞凋亡过程中如何进行调控的。上世纪80年代，国外学者发现在B细胞淋巴瘤或白血病中，有许多类型的细胞受到外界刺激时能保护细胞免于凋亡，命名为Bcl-2基因，广泛分布于从酵母到哺乳动物等各种动物体中，截止目前至少有20个Bcl-2家族成员与哺乳动物的细胞凋亡相关 [<xref ref-type="bibr" rid="hanspub.40943-ref20">20</xref>]。Bcl-2基因由239个氨基酸残基组成的，Bcl-2蛋白C末端有疏水区域，Bcl-2借此与细胞器膜相连，位于Bcl-2N端的跨膜区在Bcl-2抑制细胞凋亡过程中有重要作用。Bcl-2主要定位在线粒体外膜、核膜和内质网膜上，对细胞的生存和死亡具有重要的调控作用。</p><p>依据Bcl-2在凋亡过程中作用的不同，将Bcl-2家族成员可分为以下2类：1) 促进凋亡：包括Bax、Bad、Noxa、Puma、Bid、Bim等促进细胞凋亡蛋白，它们都缺乏BH结构域，有的只有BH3结构域，BH3结构域短肽可作用于PTP，引起线粒体细胞色素c (Cytochrome C, Cytc)释放；2) 抗凋亡蛋白：包括Bcl-2、Bcl-xl等抑制细胞凋亡蛋白，它们包含4个保守的BH结构域(BHl-BH4)。Bcl-2家族成员是通过影响线粒体膜通透性转运孔来发挥作用，Bcl-2家族成员可形成同源或异源二聚体，促凋亡和抗凋亡作用相互中和，如促凋亡蛋白占优势，则导致促凋亡因子从线粒体调控性地释放、下游Caspase活化和线粒体功能的丧失，从而促进凋亡，反之则抗凋亡。国外Atan等 [<xref ref-type="bibr" rid="hanspub.40943-ref21">21</xref>] 人研究发现Bcl-2抗凋亡机制主要有：① 作为抗氧化剂，调节细胞氧化还原状态，阻断氧化作用对细胞组成成分的破坏；② 影响细胞跨膜转运，改变钙离子分布，钙离子激活内源性内切酶和谷氨酰胺转移酶；③ 抑制有促凋亡作用的细胞色素C从线粒体释放到细胞浆；④ 保护细胞免受核酸酶损害，抑制DNA断裂。</p><p>Piao [<xref ref-type="bibr" rid="hanspub.40943-ref22">22</xref>] 等人在对人神经胶质瘤细胞凋亡的研究中结果表明PCSK9 siRNA上调Bax/Bcl-2的比值，导致Cyt-C的释放促进细胞凋亡，而过表达PCSK9降低了Cyt-C的释放，抑制细胞凋亡。Bingham等 [<xref ref-type="bibr" rid="hanspub.40943-ref23">23</xref>] 对培养的大鼠小脑颗粒状神经元(CGNs)转染绿色荧光蛋白融合的野生型和突变型NARC-1，应用激光扫描仪评估转染细胞死亡情况，发现野生型NARC-1能诱导CGNs凋亡损伤。并且这种促凋亡作用能被caspase抑制剂苄氨羟基–天冬氨酰–氟甲基酮(BAF)部分逆转。</p></sec><sec id="s7"><title>3. 外源性途径–死亡受体激活途径</title><p>外源性凋亡通路又被称死亡受体介导的凋亡传导通路，存在于细胞膜表面的死亡受体蛋白可以和其相应的配体相互结合，然后凋亡信号将会传导至细胞内，引发细胞程序性坏死，即凋亡，这在肿瘤发生、发展等方面具有非常重要的作用。目前研究发现死亡受体是位于细胞表面的I型跨膜蛋白，是肿瘤坏死因子受体(tumor necrosis factor receptor, TNFR)超家族的成员之一。死亡受体的结构由细胞膜外的半胱氨酸富集区和细胞膜内的死亡结构域组成。</p><p>目前已知的有TNFR-1、Fas、死亡受体3 (death receptor, DR3)、DR4与DR5等死亡受体家族成员。前3种死亡受体的相应配体是TNF、FasL与APO-3L，而后两种死亡受体的相应配体都是APO-2L。研究发现当受体与相应的配体结合后形成三聚体，而后形成的三聚体再与其相关的蛋白因子以及Caspase-8/Caspase-10相互结合进而形成死亡诱导信号复合体，该复合体可以进一步诱导Caspase-8/Caspase-10发生级联反应，从而导致细胞凋亡。</p><p>在外源性细胞凋亡传导通路，即死亡受体介导的凋亡传导通路中，经典的通路是Fas介导的凋亡传导通路。目前研究发现Fas介导的凋亡传导通路的作用机制为：1个具有三聚体配体的Fas结合3个Fas受体，结合后导致细胞内的死亡结构域结合衔接子蛋白Fas死亡结构域相关蛋白羧基端的死亡结构域(FADD)发生相互作用。同时，FADD的死亡效应结构域与位于Caspase-8酶原中的死亡效应结构域发生相互作用，募集细胞中的Caspase-8酶原，从而形成了由Caspase-8、Fas和FADD的三聚体，组成了死亡诱导信号复合体。Caspase-8通过蛋白质与蛋白质之间的相互作用形成二聚体，两个二聚体分子进行相互识别、相互作用，进一步互为底物而进行交叉切割反应。研究发现这种交叉切割反应是按照一定的顺序进行，首先将大小亚基之间的连接区切割，随之N端序列的构型与大亚基结构发生改变。切除了大亚基和N端前域之间的连接区以后，已经活化的Caspase-8四聚体随即就释放到细胞浆中，作用于II型Caspase，这种变化可以导致局部区域Caspase酶原浓度上升，导致相邻Caspase发生结构的二聚化，实现Caspase酶原自身的活化，这一系列的作用导致级联反应的发生，导致细胞凋亡的发生。研究已经证实，Caspase-8能够激活细胞凋亡传导下游通路的Caspase家族成员。</p><p>Sun [<xref ref-type="bibr" rid="hanspub.40943-ref24">24</xref>] 等人通过把B16F1黑色素瘤细胞转入PCSK9-/-小鼠及野生型PCSK9小鼠，两组对比发现高胆固醇可促进肝癌远处转移，PCSK9缺失对增加肝基质细胞凋亡及与远处转移有密切关系，抗凋亡因子B细胞淋巴瘤-2基因(B-cell lymphoma 2, Bcl2)在肝癌远处转移中是低表达，研究结果表明，PCSK9缺失通过降低胆固醇的水平及可能增加TNF-α介导的凋亡来减少肝癌的转移。</p></sec><sec id="s8"><title>4. 小结</title><p>PCSK9在脂质代谢等方面研究已经证实PCSK9成为治疗高胆固醇血症的新靶点。PCSK9通过与肝细胞表面的LDL-R受体结合减少LDL的吸收而影响血清LDL水平，血浆胆固醇水平升高会导致脂筏中胆固醇的积累减少细胞凋亡，促进肿瘤细胞的生长。研究发现PCSK9通过调控Bcl-2家族作用于线粒体，调控促凋亡因子和抗凋亡蛋白在细胞凋亡过程中所起的作用，PCSK9在肿瘤的发生发展中扮演着重要的角色。研究PCSK9对细胞凋亡的影响，在肿瘤细胞的增殖、运动、黏附和侵袭过程中PCSK9如何进行调控，为肿瘤诊断以及治疗策略的选择提供新的思路，为PCSK9成为抗肿瘤的新靶点，具有十分重要的意义。</p></sec><sec id="s9"><title>基金项目</title><p>1. 陕西省重点研发计划项目(编号：2020SF-048)；</p><p>2. 陕西省卫生健康科研基金项目(编号：2018D031)。</p></sec><sec id="s10"><title>文章引用</title><p>慕玉东,贺 林,张 涛. PCSK9与肿瘤发生发展关系的研究进展Research Progress on the Relationship between PCSK9 and Development of Tumor[J]. 医学诊断, 2021, 11(01): 42-46. https://doi.org/10.12677/MD.2021.111007</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40943-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Seidah, N.G., Benjamet, S., Wickham, et al. (2003) The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1(NARC-1): Liver Regenersation and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. &lt;br&gt;https://doi.org/10.1073/pnas.0335507100</mixed-citation></ref><ref id="hanspub.40943-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Humphries, S.E., Whittall, R.A., Hubbart, C.S., et al. (2006) Genetic Causes of Familial Hypercholesterolaemia in Patients in the UK: Relation to Plasma Lipid Levels and Coronary Disease Risk. Journal of Medical Genetics, 43, 943-949. &lt;br&gt;https://doi.org/10.1136/jmg.2006.038356</mixed-citation></ref><ref id="hanspub.40943-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Akram, O.N., Bermier, A., Petrides, F., et al. (2010) Beyond LDL Cholesterol, a New Role for PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1279-1281. &lt;br&gt;https://doi.org/10.1161/ATVBAHA.110.209007</mixed-citation></ref><ref id="hanspub.40943-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Maxime, D., Jadwiga, M.W., Ahmed, Z., et al. (2012) Gene Inactivation of Proprotein Convertase subtiIisir/Kex in Type 9 Reduces Atherosclerosis in Mice. Circulation, 125, 894-901.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.111.057406</mixed-citation></ref><ref id="hanspub.40943-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Melvin, J.C., Holmberg, L., Rohmann, S., et al. (2013) Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses. Journal of Cancer Epi-demiology, 2013, Article ID: 823849. &lt;br&gt;https://doi.org/10.1155/2013/823849</mixed-citation></ref><ref id="hanspub.40943-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bake, A.E. and Nelson, E.R. (2016) The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Hormones and Cancer, 7, 219-228. &lt;br&gt;https://doi.org/10.1007/s12672-016-0262-5</mixed-citation></ref><ref id="hanspub.40943-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Leignadier, J., Dalenc, F., Poirot, M., et al. (2017) Improving the Efficacy of Hormone Therapy in Breast Cancer: The Role of Cholesterol Metabolism in SERM-Mediated Autophagy, Cell Differentiation and Death. Biochemical Pharmacology, 15, 18-28. &lt;br&gt;https://doi.org/10.1016/j.bcp.2017.06.120</mixed-citation></ref><ref id="hanspub.40943-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kitahara, C.M., de Gonzalez, A.B., Freedman, N.D., et al. (2011) Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea. Journal of Clinical Oncology, 29, 1592-1598. &lt;br&gt;https://doi.org/10.1200/JCO.2010.31.5200</mixed-citation></ref><ref id="hanspub.40943-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hong, S.H., Cha, J.M., Lee, J.I., et al. (2014) Association of Hyper-LDL Cholesterolmia with Increased Risk of Colorectal Adenoma. Hepatogastroenterology, 61, 1588-1549.</mixed-citation></ref><ref id="hanspub.40943-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Agnoli, C., Grioni, S., Sieri, S., et al. (2014) Colorectal Cancer Risk and Dyslipidemia: A Case-Cohort Study Nested in an Italian Multicentre Cohort. Cancer Epidemiology, 38, 144-151. &lt;br&gt;https://doi.org/10.1016/j.canep.2014.02.002</mixed-citation></ref><ref id="hanspub.40943-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Stadler, S.C., Hacker, U. and Burkhardt, R. (2016) Cholestero Metabolism and Breast Cancer. Current Opinion in Lipidology, 27, 200-201. &lt;br&gt;https://doi.org/10.1097/MOL.0000000000000285</mixed-citation></ref><ref id="hanspub.40943-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Morris, D.L., Borhani, N.O., Fitzsimons, E., et al. (2013) Serum Cholesterol and Cancer in the Hypertension Detection and Follow-Up Program. Cancer, 52, 1754-1759.  
&lt;br&gt;https://doi.org/10.1002/1097-0142(19831101)52:9&lt;1754::AID-CNCR2820520933&gt;3.0.CO;2-J</mixed-citation></ref><ref id="hanspub.40943-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">刘业六, 钱海鑫, 秦磊, 等. 血脂相与乳腺癌远处转移的关系[J]. 中华肿瘤杂志, 2012, 34(2): 129-131.</mixed-citation></ref><ref id="hanspub.40943-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, S. and Vaux, D.L. (2002) Apoptosis. A Cinderella Caspase Takes Center Stage. Science, 297, 1290-1291.  
&lt;br&gt;https://doi.org/10.1126/science.1076118</mixed-citation></ref><ref id="hanspub.40943-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ranheim, T., Mattingsdal, M., Lindvall, J.M., et al. (2008) Ge-nome-Wide Expression Analysis of Cells Expressing Gain of Function Mutant D374Y-PCSK9. Cellular Physiology, 217, 459-467. &lt;br&gt;https://doi.org/10.1002/jcp.21519</mixed-citation></ref><ref id="hanspub.40943-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Demidyuk, V., Shubin, A.V., Gasanov, E.V., et al. (2013) Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios. PLoS ONE, 8, e55752.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0055752</mixed-citation></ref><ref id="hanspub.40943-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lan, H., Pang, L., Smith, M.M., et al. (2010) Proprotein Con-vertase Subtilisin/Kexin Type 9(PCSK9) Affects Gene Expression Pathways beyond Cholesterol Metabolism in Liver Cells. Journal of Cellular Physiology, 224, 273-281.  
&lt;br&gt;https://doi.org/10.1002/jcp.22130</mixed-citation></ref><ref id="hanspub.40943-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Poirier, S., Mayer, G., Benjannet, S., et al. (2008) The Proprotein Con-vertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. Journal of Biological Chemistry, 283, 2363-2372. &lt;br&gt;https://doi.org/10.1074/jbc.M708098200</mixed-citation></ref><ref id="hanspub.40943-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Seidah, N.G. and Prat, A. (2012) The Biology and Therapeutic Targeting of the Proprotein Convertases. Nature Reviews Drug Discovery, 11, 367-383. &lt;br&gt;https://doi.org/10.1038/nrd3699</mixed-citation></ref><ref id="hanspub.40943-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dive, C. and Hickman, J.A. (2001) Drug-Target Interactions: Only the First Step in the Commitment to a Programmed Cell Death. British Journal of Cancer, 64, 192-196. &lt;br&gt;https://doi.org/10.1038/bjc.1991.269</mixed-citation></ref><ref id="hanspub.40943-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gross, A., et al. (1999) BCL-2 Family Members and the Mitochondria in Apoptosis. Genes &amp; Development, 13, 1899-1911. &lt;br&gt;https://doi.org/10.1101/gad.13.15.1899</mixed-citation></ref><ref id="hanspub.40943-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ming, X.P., Ji, W.B., Peng, F.Z., et al. (2015) PCSK9 Regulates Apoptosis in Human Neuroglioma U251 Cells via Mitochondrial Signaling Pathways. International Journal of Clinical and Experimental Pathology, 8, 2787-2794.</mixed-citation></ref><ref id="hanspub.40943-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bingham, B., Shen, R., Kotnis, S., et al. (2006) Proapoptotic Effects of NARC1 (= PCSK9), the Gene Encoding a Novel Serine Pro-teinase. Cytometry A, 69, 1123-1131. &lt;br&gt;https://doi.org/10.1002/cyto.a.20346</mixed-citation></ref><ref id="hanspub.40943-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Essalmani, R., Day, R., et al. (2012) Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver. Neoplasia, 14, 1122-1131. &lt;br&gt;https://doi.org/10.1593/neo.121252</mixed-citation></ref></ref-list></back></article>